Key Statistics
Market Cap
$21.00B
Shares Outstanding
614.9M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Oct 5, 2010
Round Lot
100
Locale
US
Trading Data
Day Open
$32.34
Day High
$34.19
Day Low
$32.34
Volume
3.09M
VWAP
$33.65
Prev Close
$32.65
Transactions
--
Acc. Volume
--
About Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Identifiers
- CIK
- 0001434265
- Composite FIGI
- BBG004MPKM64
- Share Class FIGI
- BBG004MPKMY3
- Ticker Root
- GMAB
About Genmab A/S ADS (GMAB) Stock
Genmab A/S ADS (GMAB) closed the 2026-09-15 session at $34.15, up 4.59% versus the previous close (+1.50). The stock opened at $32.34 and traded between $32.34 and $34.19 during that session. Session trading volume was 3.1M shares. The volume-weighted average price (VWAP) is $33.65.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Genmab A/S ADS has a market capitalization of $21.00 billion. GMAB is listed on the XNAS exchange. The company employs approximately 3,119 people. The recorded listing date is 2010-10-05.
On this page you can find market GMAB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.